Accordingly, the quantification of PCNA-positive cells in the corresponding slides (Figure 7D) indicated that tumor proliferation was strongly diminished by regorafenib/A-1331852 co-administration (100 ± 88), compared to regorafenib- or vehicle-treated mice (869 ± 320 and 1573 ± 395, respectively). This evidence concerns the gene PCNA and neoplasm.